- A + A BENGALURU (Jan 20): Shares in Unilever inched roughly 2% higher on Thursday after the consumer goods giant said it would not raise its rejected £50 billion (US$68 billion) offer for GlaxoSmithKline's (GSK) consumer healthcare business. Shares in GSK fell by similar levels to the bottom of the FTSE 100 after the Dove and Lifebuoy soaps maker late on Wednesday effectively ended its pursuit of a business that the pharmaceuticals company plans to spin off later this year. GSK said on Saturday it had rejected three approaches from Unilever for the business which makes Sensodyne toothpaste and painkillers such as Panadol and is 32% owned by US drug maker Pfizer. The final proposal made on Dec 20 comprised £41.7 billion in cash and £8.3 billion in Unilever shares, but GSK said it failed to reflect the intrinsic value of the business and its potential. Unilever's decision not to increase its bid raises questions about its strategy under chief executive officer … [Read more...] about Unilever shares gain after opting not to lift bid for GSK consumer assets
Usmf consumer goods
If you're looking for better-than-average dividend yields, there's a pharmaceutical stock you need to take a look at. At recent prices, AbbVie ( NYSE:ABBV ) offers a 4.1% dividend yield that's impossible to ignore. Over the past year, the average dividend-paying stock in the S&P 500 index delivered a lousy 1.3% yield. If the big yield AbbVie offers seems a little too good to be true, it's because there's a catch. Image source: Getty Images. Why the above-average yield? In a nutshell, fear of declining sales for AbbVie's lead drug, Humira, is the reason AbbVie offers a huge dividend yield that is more than double the benchmark average. It's been 20 years since the FDA first approved this injectable drug for the treatment of rheumatoid arthritis. U.S. Humira sales contributed $4.6 billion to AbbVie's top line during the third quarter, so replacing lost revenue from this drug is going to be a major challenge. Biosimilar competition in the EU broke through the … [Read more...] about Is AbbVie a Good Dividend Stock to Buy Right Now?
Share to Twitter Share to Linkedin Paul Tudor Jones' JUST Capital aims to find large U.S. companies that engage in "just business ... [+] behavior." Kevin Mazur/Getty Images Goldman Sachs Asset Management is jumping into the do-good investing game with a new ETF: JUST. The new fund aims to track an index created by JUST Capital , a nonprofit that does research to find large U.S. companies engaging in “just business behavior.” (Disclosure: Forbes ’ chief content officer Randall Lane is on the board of Just Capital, and Forbes publishes JUST Capital’s top 100-ranked companies each year.) Cofounded in 2013 by billionaire investor Paul Tudor Jones II and thought leaders like Deepak Chopra and Arianna Huffington, JUST Capital has surveyed 72,000 Americans to understand the business practices related to environmental, social and governance (ESG) issues that matter most to them. Using those priorities, it scores Russell 1000 … [Read more...] about Feel Good, Get Rich With New Goldman Sachs Paul Tudor Jones ETF
For more than a decade, growth stocks have been the talk of Wall Street. Historically low lending rates have rolled out the red carpet for fast-paced companies and allowed them to borrow cheaply in order to hire, acquire, and innovate. But what you might not realize is that value stocks have actually outperformed growth stocks over the very long run. Since value stocks are profitable and time-tested, they're the perfect place for patient investors to put their money to work. Below are five value stocks that could make you richer in 2022. Image source: Getty Images. General Motors The days of General Motors ( NYSE:GM ) being just another stagnant auto stock are gone. The electrification of automobiles has placed a multi-decade growth opportunity on the company's doorstep, and it'll undoubtedly run with it. In June, General Motors announced plans to up its investments in electric vehicles (EVs), autonomous vehicles, and batteries to $35 billion by 2025 . The … [Read more...] about 5 Value Stocks That Can Make You Richer in 2022
Every major U.S. stock index has taken a step backward since the start of December. U.S. equities have reversed course this month because of inflationary pressures, the omicron variant, and year-end tax-loss harvesting. What's the best strategy to navigate this chaotic market? Dividend stocks are always worth owning as part of a well-rounded portfolio. Equities that dole out regular dividends to shareholders, after all, can smooth out the rough patches during volatile periods in the market. What's more, these types of stocks come with a built-in level of safety because of their attractiveness as passive income vehicles. Which dividend stocks are must-owns right now? The top pharma stocks Amgen ( NASDAQ:AMGN ) , Bristol Myers Squibb ( NYSE:BMY ) , and GlaxoSmithKline ( NYSE:GSK ) are all worth adding to your portfolio soon. Here's a look at the key features associated with each of these three rock-solid dividend plays . Image source: Getty Images. 1. … [Read more...] about 3 Must-Own Dividend Stocks in This Chaotic Market
While you might not like what I'm about to say, it's the truth: A stock market crash or steep correction may be brewing . Since the beginning of 1950, the benchmark S&P 500 has undergone 38 double-digit percentage declines, equating to roughly one every 1.9 years. Even though Wall Street doesn't strictly adhere to averages, it's important to recognize that crashes and corrections are a normal part of the investing cycle. On the other hand, dips in the market are also an incredible opportunity to pick up high-quality stocks at a discount. While there are numerous investing strategies that can make you richer over time, dividend stocks have a proven track record of outperforming their non-dividend-paying peers. Since dividend stocks are almost always profitable and time-tested, they're the perfect way to put money to work in a volatile market. If a stock market crash does occur in 2022, the following four dividend stocks would make for perfect buys. Image source: … [Read more...] about 4 Perfect Dividend Stocks to Buy if There’s a Stock Market Crash
Are some major acquisitions on the way in the biopharmaceutical industry this year? That remains to be seen. But there are some deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen. In this Motley Fool Live video recorded on Jan. 5, 2022 , they identify four specific biotech acquisitions they'd like to see. Keith Speights: Let's switch gears. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. There were a few, but not as many. Brian, what are some acquisitions that you'd like to see take place in the biopharmaceutical world in 2022. Brian Orelli: I'd like to see Bristol-Myers Squibb ( NYSE:BMY ) acquire Seagen ( NASDAQ:SGEN ) . I own Seagen. There would be some synergies on the commercial sales side. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. It could find some synergies in having salespeople sell just the same set of drugs … [Read more...] about 4 Biotech Acquisitions We’d Like to See in 2022
Shares of Vertex Pharmaceuticals ( NASDAQ:VRTX ) spiked recently in response to good news for an experimental new drug. The past year has been marked by one development setback after another, but recent developments make it look like it has a chance to come back stronger than ever. Successful results from a clinical trial with a drug that isn't part of the company's successful cystic fibrosis franchise are generating a lot of stock market buzz for Vertex Pharmaceuticals again. Here's a look past the top-line results to see if now's a good time to buy the stock. Image source: Getty Images. Why Vertex Pharmaceuticals stock spiked On Dec. 1, 2021, Vertex Pharmaceuticals' stock jumped after the company posted results from a human proof-of-concept study with VX-147. This is a first-in-class candidate for the treatment of APOL1-mediated kidney disease, a rare inherited condition that lacks effective treatment options. The amount of protein in patients' urine samples, or … [Read more...] about Is Vertex Pharmaceuticals Stock a Buy Now?
The healthcare industry isn't always known for record-high returns, but the resilience, stable growth, and often, dividends, that these companies deliver are a tremendous draw for investors of all trading styles looking to build their portfolios. However, as companies across all industries have faced extreme volatility in recent months, some healthcare stocks have been hit harder than others. Teladoc ( NYSE:TDOC ) is certainly one of them. In this segment of Backstage Pass , recorded on Dec. 22 , Fool contributor Rachel Warren explains her investing thesis for Teladoc and why the stock is still a top contender for long-term investors to consider right now. Rachel Warren : I'm going to go with another company that is in the same boat in the sense that the business is still looking really good, but boy, the market has not been kind to the stock, and that would be Teladoc. This is a company I have talked a lot about over the past few months. This is a company … [Read more...] about This Beaten-Down Healthcare Stock Could Skyrocket in 2022
Since the stock market bottomed out in March 2020, investors have enjoyed historic gains. It took less than 17 months for the broad-based S&P 500 to double from its bear market low. Furthermore, the widely followed index came close to tripling its long-term average annual return in 2021. Despite this incredible outperformance, amazing deals remain. Patient investors who buy into innovative companies with clear-cut competitive advantages have a real chance to see their initial investment compound many times over. If you have cash ready to invest and are willing to let time be your ally, the following four stocks all have the tools to turn $100,000 into $1 million by 2030. Image source: Getty Images. Teladoc Health There's no sugarcoating it: telehealth giant Teladoc Health ( NYSE:TDOC ) was one of 2021's biggest disappointments. After skyrocketing during the initial stages of the coronavirus pandemic, concerns about larger-than-expected losses tied to its … [Read more...] about 4 Stocks That Can Turn $100,000 Into $1 Million by 2030